SPARC gene expression is increased in diabetes-related mesenteric vascular hypertrophy.

The anti-adhesive extracellular matrix protein SPARC (secreted protein and rich in cysteine; osteonectin or BM-40) has been implicated in the regulation of matrix turnover, cell migration, and proliferation. The present study sought to examine whether modulation in the expression of this protein may play a role in diabetes-associated vascular remodeling. SPARC mRNA and protein were measured in mesenteric vessels of diabetic rats and controls. Hypertrophy of mesenteric vessels was noted after 3 and 32 weeks of diabetes as revealed by the increase in mesenteric vessel wet weight and an increased wall/lumen ratio. SPARC mRNA was sparsely present in intima and adventitia of control vessels. There was a marked increase in SPARC gene expression in the intima and adventitia of mesenteric vessels after 1, 3, and 32 weeks of diabetes. SPARC protein was demonstrated in the vessel wall in control animals and was increased in the mesenteric vessels of diabetic rats after 1 and 32 weeks of diabetes. Administration of the inhibitor of advanced glycation end-product formation, aminoguanidine, to diabetic rats attenuated both the hypertrophic response in mesenteric vessels and the overexpression of SPARC mRNA and protein without affecting glycemic control or food intake. In summary, diabetes-related mesenteric vascular hypertrophy is associated with an increase in SPARC expression in the vessel wall. The modulation of SPARC expression in mesenteric vessels of diabetic rats might be of pathogenetic significance in the development of vascular remodeling in diabetes.

[1]  M. Cooper,et al.  Cellular mechanisms of diabetic vascular hypertrophy. , 1999, Microvascular research.

[2]  M. Cooper,et al.  Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin‐diabetes‐associated mesenteric vascular hypertrophy independently of their hypotensive action , 1998, Journal of hypertension.

[3]  M. Cooper,et al.  Secreted protein acidic and rich in cysteine expression after subtotal nephrectomy and blockade of the renin-angiotensin system. , 1997, Journal of the American Society of Nephrology : JASN.

[4]  G. Jerums,et al.  Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. , 1997, The Journal of clinical investigation.

[5]  M. Reed,et al.  SPARC is expressed in renal interstitial fibrosis and in renal vascular injury. , 1996, Kidney international.

[6]  G. Jerums,et al.  Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. , 1996, Kidney international.

[7]  G. Jerums,et al.  SPARC gene expression is reduced in early diabetes-related kidney growth. , 1995, Kidney international.

[8]  A. Gown,et al.  Distribution of SPARC in normal and neoplastic human tissue. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[9]  M. Cooper,et al.  Diabetes-Associated Mesenteric Vascular Hypertrophy Is Attenuated by Angiotensin-Converting Enzyme Inhibition , 1994, Diabetes.

[10]  K. Chada,et al.  Expression of the helix-loop-helix protein, Id, during branching morphogenesis in the kidney. , 1994, Kidney international.

[11]  E. Sage,et al.  The biology of SPARC, a protein that modulates cell‐matrix interactions , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  Z. Werb,et al.  SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway , 1993, The Journal of cell biology.

[13]  M. Mulvany,et al.  Small artery structure in hypertension. Dual processes of remodeling and growth. , 1993, Hypertension.

[14]  V. Monnier,et al.  Maillard Reaction-Mediated Molecular Damage to Extracellular Matrix and Other Tissue Proteins in Diabetes, Aging, and Uremia , 1992, Diabetes.

[15]  A. Dodge,et al.  Cell-Cell Interactions in Diabetic Angiopathy , 1992, Diabetes Care.

[16]  M. Iruela-Arispe,et al.  Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. , 1992, The Journal of biological chemistry.

[17]  R. Ross,et al.  The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Chiquet‐Ehrismann Anti-adhesive molecules of the extracellular matrix. , 1991, Current opinion in cell biology.

[19]  P. Bornstein,et al.  Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. , 1991, The Journal of biological chemistry.

[20]  R. Timpl,et al.  Calcium-dependent binding of basement membrane protein BM-40 (osteonectin, SPARC) to basement membrane collagen type IV. , 1991, European journal of biochemistry.

[21]  M. Mulvany,et al.  Angiotensin II Causes Vascular Hypertrophy in Part by a Non‐pressor Mechanism , 1991, Hypertension.

[22]  J. Wrana,et al.  Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. , 1991, European journal of biochemistry.

[23]  M. Mulvany,et al.  Functional properties in vitro of systemic small arteries from rabbits fed a cholesterol-rich diet for 12 weeks. , 1991, Clinical science.

[24]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[25]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[26]  R. Timpl,et al.  Purification and tissue distribution of a small protein (BM-40) extracted from a basement membrane tumor. , 1986, European journal of biochemistry.

[27]  R. Buñag Validation in awake rats of a tail-cuff method for measuring systolic pressure. , 1973, Journal of applied physiology.